

# OVARY STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>		STAGE CATEGORY DEFINITIONS		PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>	
<input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery		<b>TUMOR SIZE:</b> _____		<b>LATERALITY:</b> <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral	
<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery					
<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>	<b>PRIMARY TUMOR (T)</b>		<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>
<input type="checkbox"/> TX		Primary tumor cannot be assessed		<input type="checkbox"/> TX	
<input type="checkbox"/> T0		No evidence of primary tumor		<input type="checkbox"/> T0	
<input type="checkbox"/> T1	I	Tumor limited to ovaries (one or both)		<input type="checkbox"/> T1	I
<input type="checkbox"/> T1a	IA	Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T1a	IA
<input type="checkbox"/> T1b	IB	Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T1b	IB
<input type="checkbox"/> T1c	IC	Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T1c	IC
<input type="checkbox"/> T2	II	Tumor involves one or both ovaries with pelvic extension and/or implants		<input type="checkbox"/> T2	II
<input type="checkbox"/> T2a	IIA	Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T2a	IIA
<input type="checkbox"/> T2b	IIB	Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T2b	IIB
<input type="checkbox"/> T2c	IIC	Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings		<input type="checkbox"/> T2c	IIC
<input type="checkbox"/> T3	III	Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis		<input type="checkbox"/> T3	III
<input type="checkbox"/> T3a	IIIA	Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)		<input type="checkbox"/> T3a	IIIA
<input type="checkbox"/> T3b	IIIB	Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension		<input type="checkbox"/> T3b	IIIB
<input type="checkbox"/> T3c	IIIC	Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis		<input type="checkbox"/> T3c	IIIC
		<i>Note: Liver capsule metastasis T3/Stage III; liver parenchymal metastasis M1/Stage IV. Pleural effusion must have positive cytology for M1/Stage IV.</i>			
<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>	<b>REGIONAL LYMPH NODES (N)</b>		<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>
<input type="checkbox"/> NX		Regional lymph nodes cannot be assessed		<input type="checkbox"/> NX	
<input type="checkbox"/> N0		No regional lymph node metastasis		<input type="checkbox"/> N0	
<input type="checkbox"/> N1	IIIC	Regional lymph node metastasis		<input type="checkbox"/> N1	IIIC
<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>	<b>DISTANT METASTASIS (M)</b>		<b>TNM CATEGORY</b>	<b>FIGO STAGE</b>
<input type="checkbox"/> M0		No distant metastasis (no pathologic M0; use clinical M to complete stage group)		<input type="checkbox"/> M0	
<input type="checkbox"/> M1	IV	Distant metastasis (excludes peritoneal metastasis)		<input type="checkbox"/> M1	IV

<b>HOSPITAL NAME/ADDRESS</b>	<b>PATIENT NAME/INFORMATION</b>
------------------------------	---------------------------------

*(continued on next page)*

# Ovary Staging Form

## Anatomic Stage • Prognostic Groups

CLINICAL				PATHOLOGIC			
GROUP	T	N	M	GROUP	T	N	M
<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> I	T1	N0	M0
<input type="checkbox"/> IA	T1a	N0	M0	<input type="checkbox"/> IA	T1a	N0	M0
<input type="checkbox"/> IB	T1b	N0	M0	<input type="checkbox"/> IB	T1b	N0	M0
<input type="checkbox"/> IC	T1c	N0	M0	<input type="checkbox"/> IC	T1c	N0	M0
<input type="checkbox"/> II	T2	N0	M0	<input type="checkbox"/> II	T2	N0	M0
<input type="checkbox"/> IIA	T2a	N0	M0	<input type="checkbox"/> IIA	T2a	N0	M0
<input type="checkbox"/> IIB	T2b	N0	M0	<input type="checkbox"/> IIB	T2b	N0	M0
<input type="checkbox"/> IIC	T2c	N0	M0	<input type="checkbox"/> IIC	T2c	N0	M0
<input type="checkbox"/> III	T3	N0	M0	<input type="checkbox"/> III	T3	N0	M0
<input type="checkbox"/> IIIA	T3a	N0	M0	<input type="checkbox"/> IIIA	T3a	N0	M0
<input type="checkbox"/> IIIB	T3b	N0	M0	<input type="checkbox"/> IIIB	T3b	N0	M0
<input type="checkbox"/> IIIC	T3c	N0	M0	<input type="checkbox"/> IIIC	T3c	N0	M0
<input type="checkbox"/>	Any T	N1	M0	<input type="checkbox"/>	Any T	N1	M0
<input type="checkbox"/> IV	Any T	Any N	M1	<input type="checkbox"/> IV	Any T	Any N	M1
<input type="checkbox"/> Stage unknown				<input type="checkbox"/> Stage unknown			

### Prognostic Factors (Site-Specific Factors)

REQUIRED FOR STAGING: None

#### Clinically Significant:

FIGO stage: \_\_\_\_\_

Gross residual tumor after primary cyto-reductive surgery: \_\_\_\_\_ (present, absent, unknown, "y" meaning patient received chemotherapy prior to surgery)

Residual tumor volume after primary cyto-reductive surgery: \_\_\_\_\_ (no gross, ≤1 cm, >1 cm, unknown, "y" meaning patient received chemotherapy prior to surgery)

Residual tumor location following primary cyto-reductive surgery: \_\_\_\_\_ ("y" indicates patient received chemotherapy prior to surgery)

Malignant ascites volume: \_\_\_\_\_

#### General Notes:

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

**m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

**y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

**r prefix** indicates a recurrent tumor when staged after a disease-free interval and is identified by the "r" prefix: rTNM.

**a prefix** designates the stage determined at autopsy: aTNM.

#### Histologic Grade (G) (also known as overall grade)

##### Grading system

- ☐ 2 grade system  
☐ 3 grade system  
☐ 4 grade system  
☐ No 2, 3, or 4 grade system is available

##### Grade

- ☐ Grade I or 1  
☐ Grade II or 2  
☐ Grade III or 3  
☐ Grade IV or 4

#### Additional Descriptors

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- ☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified  
☐ Lymph-Vascular Invasion Present/Identified  
☐ Not Applicable  
☐ Unknown/Indeterminate

HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION

(continued from previous page)

## OVARY STAGING FORM

### **Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

### **General Notes (continued):**

**surgical margins** is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

**neoadjuvant treatment** is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

☐ Clinical stage was used in treatment planning (describe): \_\_\_\_\_

☐ National guidelines were used in treatment planning ☐ NCCN ☐ Other (describe): \_\_\_\_\_

\_\_\_\_\_  
Physician signature

\_\_\_\_\_  
Date/Time

**HOSPITAL NAME/ADDRESS**




**PATIENT NAME/INFORMATION**

(continued on next page)

## OVARY STAGING FORM

### Illustration

Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION

(continued from previous page)